Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort
Breast Cancer Research and Treatment · 2024-08 · 206 (3) · 551-559
DOI: 10.1007/s10549-024-07324-8 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 04.05.2024. Verfasst von Rodrigo Sánchez-Bayona und 18 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain. Hauptthemen laut MEDLINE: Everolimus, Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Everolimus in combination with endocrine therapy (ET) was formerly approved as 2nd-line therapy in HR(+)/HER2(-) advanced breast cancer (aBC) patients (pts) progressing during or after a non-steroidal aromatase inhibitor (NSAI). Since this approval, the treatment landscape of aBC has changed dramatically, particularly with the arrival of CDK 4-6 inhibitors. Endocrine monotherapy after progression to CDK4/6 inhibitors has shown a limited progression-free survival (PFS), below 3 months. Evidence of the efficacy of everolimus plus ET after CDK4/6 inhibitors is scarce. METHODS: A retrospective observational study of patients with aBC treated with everolimus and ET beyond CDK4/6-i progression compiled from February 2015 to December 2022 in 4 Spanish hospitals was performed. Clinical and demographic data were collected from medical records. The main objective was to estimate the median progression-free survival (mPFS). Everolimus adverse events (AE) were registered. Quantitative variables were summarized with medians; qualitative variables with proportions and the Kaplan-Meier method were used for survival estimates. RESULTS: One hundred sixty-one patients received everolimus plus ET (exemestane: 96, fulvestrant: 54, tamoxifen: 10, unknown: 1) after progressing on a CDK4/6 inhibitor. The median follow-up time was 15 months (interquartile range: 1-56 months). The median age at diagnosis was 49 years (range: 35-90 years). The estimated mPFS was 6.0 months (95%CI 5.3-7.8 months). PFS was longer in patients with previous CDK4/6 inhibitor therapy lasting for > 18 months (8.7 months, 95%CI 6.6-11.3 months), in patients w/o visceral metastases (8.0 months, 95%CI 5.8-10.5 months), and chemotherapy-naïve in the metastatic setting (7.2 months, 95%CI 5.9-8.4 months). CONCLUSION: This retrospective analysis cohort of everolimus plus ET in mBC patients previously treated with a CDK4/6 inhibitor suggests a longer estimated mPFS when compared with the mPFS with ET monotherapy obtained from current randomized clinical data. Everolimus plus ET may be considered as a valid control arm in novel clinical trial designs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
- Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain.
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, C/Dr Esquerdo, 46, 28007, Madrid, Spain.
- Medical Oncology, Hospital Universitario Infanta Cristina, Parla, Spain.
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, C/Dr Esquerdo, 46, 28007, Madrid, Spain. mmartin@geicam.org.
Zitieren
APA
Sánchez-Bayona, R., Lopez de Sa, A., Jerez Gilarranz, Y., Sanchez de Torre, A., Alva, M., Echavarria, I., Moreno, F., Tolosa, P., Herrero Lopez, B., de Luna, A., Lema, L., Gamez Casado, S., Madariaga, A., López-Tarruella, S., Manso, L., Bueno-Muiño, C., Garcia-Saenz, J. A., Ciruelos, E., & Martin, M. (2024). Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort. Breast Cancer Research and Treatment, 206(3), 551-559. https://doi.org/10.1007/s10549-024-07324-8
Vancouver
Sánchez-Bayona R, Lopez de Sa A, Jerez Gilarranz Y, Sanchez de Torre A, Alva M, Echavarria I, et al. Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort. Breast Cancer Research and Treatment. 2024;206(3):551-559. doi:10.1007/s10549-024-07324-8
BibTeX
@article{SnchezBayona2024,
author = {Sánchez-Bayona, Rodrigo and Lopez de Sa, Alfonso and Jerez Gilarranz, Yolanda and Sanchez de Torre, Ana and Alva, Manuel and Echavarria, Isabel and Moreno, Fernando and Tolosa, Pablo and Herrero Lopez, Blanca and de Luna, Alicia and Lema, Laura and Gamez Casado, Salvador and Madariaga, Ainhoa and López-Tarruella, Sara and Manso, Luis and Bueno-Muiño, Coralia and Garcia-Saenz, Jose A and Ciruelos, Eva and Martin, Miguel},
title = {Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort},
journal = {Breast Cancer Research and Treatment},
year = {2024},
volume = {206},
number = {3},
pages = {551--559},
doi = {10.1007/s10549-024-07324-8}
}
EUVIMED